Immunogenicity and reactogenicity of a reduced schedule of a 4-component capsular group B meningococcal vaccine: a randomized controlled trial in infants
<strong>Background<br></strong> The 4-component capsular group B meningococcal vaccine (4CMenB) was licensed as a 4-dose infant schedule but introduced into the United Kingdom as 3 doses at 2, 4, and 12 months of age. We describe the immunogenicity and reactogenicity of the 2 + 1 s...
| Autores principales: | , , , , , , , , , , , , , , |
|---|---|
| Formato: | Journal article |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2020
|